1. P1154: STUDY ZILO-301: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF ZILOVERTAMAB PLUS IBRUTINIB VS IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA. (23rd June 2022) Authors: Yazji, S.; Hamburger, S.; Wang, Y.; Yavrom, S.; Pietrofeso, A.; Bliss, R.; Breitmeyer, J. B.; Dreyling, M.; Wang, M. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1041 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗